PREDICT HF: Risk stratification in advanced heart failure using novel hemodynamic parameters.


Journal

Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272

Informations de publication

Date de publication:
Jun 2024
Historique:
revised: 29 01 2024
received: 25 10 2023
accepted: 14 03 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 5 6 2024
Statut: ppublish

Résumé

Invasive hemodynamics are fundamental in assessing patients with advanced heart failure (HF). Several novel hemodynamic parameters have been studied; however, the relative prognostic potential remains ill-defined. Advanced hemodynamic parameters provide additional prognostication beyond the standard hemodynamic assessment. Patients from the PRognostic Evaluation During Invasive CaTheterization for Heart Failure (PREDICT-HF) registry who underwent right heart catheterization (RHC) were included in the analysis. The primary endpoint was survival to orthotopic heart transplant (OHT) or durable left ventricular assist device (LVAD), or death within 6 months of RHC. Of 846 patients included, 176 (21%) met the primary endpoint. In a multivariate model that included traditional hemodynamic variables, pulmonary capillary wedge pressure (PCWP) (OR: 1.10, 1.04-1.15, p < .001), and cardiac index (CI) (OR: 0.86, 0.81-0.92, p < .001) were shown to be predictive of adverse outcomes. In a separate multivariate model that incorporated advanced hemodynamic parameters, cardiac power output (CPO) (OR: 0.76, 0.71-0.83, p < .001), aortic pulsatility index (API) (OR: 0.94, 0.91-0.96, p < .001), and pulmonary artery pulsatility index (OR: 1.02, 1.00-1.03, p .027) were all significantly associated with the primary outcome. Positively concordant API and CPO afforded the best freedom from the endpoint (94.7%), whilst negatively concordant API and CPO had the worst freedom from the endpoint (61.5%, p < .001). Those with discordant API and CPO had similar freedom from the endpoint. The advanced hemodynamic parameters API and CPO are independently associated with death or the need for OHT or LVAD within 6 months. Further prospective studies are needed to validate these parameters and elucidate their role in patients with advanced HF.

Sections du résumé

BACKGROUND BACKGROUND
Invasive hemodynamics are fundamental in assessing patients with advanced heart failure (HF). Several novel hemodynamic parameters have been studied; however, the relative prognostic potential remains ill-defined.
HYPOTHESIS OBJECTIVE
Advanced hemodynamic parameters provide additional prognostication beyond the standard hemodynamic assessment.
METHODS METHODS
Patients from the PRognostic Evaluation During Invasive CaTheterization for Heart Failure (PREDICT-HF) registry who underwent right heart catheterization (RHC) were included in the analysis. The primary endpoint was survival to orthotopic heart transplant (OHT) or durable left ventricular assist device (LVAD), or death within 6 months of RHC.
RESULTS RESULTS
Of 846 patients included, 176 (21%) met the primary endpoint. In a multivariate model that included traditional hemodynamic variables, pulmonary capillary wedge pressure (PCWP) (OR: 1.10, 1.04-1.15, p < .001), and cardiac index (CI) (OR: 0.86, 0.81-0.92, p < .001) were shown to be predictive of adverse outcomes. In a separate multivariate model that incorporated advanced hemodynamic parameters, cardiac power output (CPO) (OR: 0.76, 0.71-0.83, p < .001), aortic pulsatility index (API) (OR: 0.94, 0.91-0.96, p < .001), and pulmonary artery pulsatility index (OR: 1.02, 1.00-1.03, p .027) were all significantly associated with the primary outcome. Positively concordant API and CPO afforded the best freedom from the endpoint (94.7%), whilst negatively concordant API and CPO had the worst freedom from the endpoint (61.5%, p < .001). Those with discordant API and CPO had similar freedom from the endpoint.
CONCLUSION CONCLUSIONS
The advanced hemodynamic parameters API and CPO are independently associated with death or the need for OHT or LVAD within 6 months. Further prospective studies are needed to validate these parameters and elucidate their role in patients with advanced HF.

Identifiants

pubmed: 38838029
doi: 10.1002/clc.24277
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e24277

Informations de copyright

© 2024 The Authors. Clinical Cardiology published by Wiley Periodicals, LLC.

Références

Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2013 update: a report from the American Heart Association. Circulation. 2013;127:6. doi:10.1161/CIR.0b013e31828124ad
Crespo‐Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:1505‐1535. doi:10.1002/ejhf.1236
Ammar KA, Jacobsen SJ, Mahoney DW, et al. Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community. Circulation. 2007;115:1563‐1570. doi:10.1161/CIRCULATIONAHA.106.666818
Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625‐1633. doi:10.1001/jama.294.13.1625
Cooper LB, Mentz RJ, Stevens SR, et al. Hemodynamic predictors of heart failure morbidity and mortality: fluid or flow. J Card Failure. 2016;22:182‐189. doi:10.1016/j.cardfail.2015.11.012
Kochav SM, Flores RJ, Truby LK, Topkara VK. Prognostic impact of pulmonary artery pulsatility index (PAPi) in patients with advanced heart failure: insights from the ESCAPE trial. J Card Failure. 2018;24:453‐459. doi:10.1016/j.cardfail.2018.03.008
Belkin MN, Alenghat FJ, Besser SA, et al. Aortic pulsatility index predicts clinical outcomes in heart failure: a sub‐analysis of the ESCAPE trial. ESC Heart Failure. 2021;8:1522‐1530. doi:10.1002/ehf2.13246
Belkin MN, Kalantari S, Kanelidis AJ, et al. Aortic pulsatility index: a novel hemodynamic variable for evaluation of decompensated heart failure. J Card Failure. 2021;27:1045‐1052. doi:10.1016/j.cardfail.2021.05.010
Fincke R, Hochman JS, Lowe AM, et al. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44:340‐348. doi:10.1016/j.jacc.2004.03.060
Creager MA, Faxon DP, Halperin JL, et al. Determinants of clinical response and survival in patients with congestive heart failure treated with captopril. Am Heart J. 1982;104:1147‐1154. doi:10.1016/0002-8703(82)90043-6
Wilson JR, Schwartz JS, St. John Sutton M, et al. Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity. J Am Coll Cardiol. 1983;2:403‐410. doi:10.1016/s0735-1097(83)80265-4
Franciosa JA. Why patients with heart failure die: hemodynamic and functional determinants of survival. Circulation. 1987;75:IV20‐IV27.
Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting‐enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257‐267. doi:10.1161/01.cir.73.2.257
Opotowsky AR, Hess E, Maron BA, et al. Thermodilution vs estimated fick cardiac output measurement in clinical practice: an analysis of mortality from the veterans affairs clinical assessment, reporting, and tracking (VA CART) program and vanderbilt university. JAMA Cardiol. 2017;2:1090‐1099. doi:10.1001/jamacardio.2017.2945
Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fetters JK, Leier CV. Factors influencing the one‐year mortality of dilated cardiomyopathy. Am J Cardiol. 1984;54:147‐152. doi:10.1016/0002-9149(84)90320-5
Garan AR, Kanwar M, Thayer KL, et al. Complete hemodynamic profiling with pulmonary artery catheters in cardiogenic shock is associated with lower in‐hospital mortality. JACC: Heart Failure. 2020;8:903‐913. doi:10.1016/j.jchf.2020.08.012
Thayer KL, Zweck E, Ayouty M, et al. Invasive hemodynamic assessment and classification of in‐hospital mortality risk among patients with cardiogenic shock. Circulation: Heart Failure. 2020;13:e007099. doi:10.1161/CIRCHEARTFAILURE.120.007099
Verbrugge FH, Tang WHW, Mullens W. Renin‐angiotensin‐aldosterone system activation during decongestion in acute heart failure. JACC: Heart Failure. 2015;3:108‐111. doi:10.1016/j.jchf.2014.10.005
Belkin MN, Shah J, Neyestanak ME, Burkhoff D, Grinstein J. Should we be using aortic pulsatility index over cardiac power output in heart failure cardiogenic shock? Circulation: Heart Failure. 2022;15:e009601. doi:10.1161/CIRCHEARTFAILURE.122.009601
Grinstein J, Houston BA, Nguyen AB, et al. Standardization of the right heart catheterization and the emerging role of advanced hemodynamics in heart failure. J Card Fail. 2023;29(11):1543‐1555. doi:10.1016/j.cardfail.2023.08.009
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79:e263‐e421. doi:10.1016/j.jacc.2021.12.012
Shore S, Golbus JR, Aaronson KD, Nallamothu BK. Changes in the United States adult heart allocation policy: challenges and opportunities. Circulation: Cardiovasc Qual Outcomes. 2020;13:e005795. doi:10.1161/CIRCOUTCOMES.119.005795

Auteurs

Nicole Cyrille-Superville (N)

Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.

Sriram D Rao (SD)

Department of Medicine, Medstar Washington Hospital Center, Division of Cardiology, Georgetown University, Washington, District of Columbia, USA.

Jason P Feliberti (JP)

University of South Florida Heart and Vascular Institute, Transplant Cardiology, Tampa, Florida, USA.

Priyesh A Patel (PA)

Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.

Kamala Swayampakala (K)

Sanger Heart and Vascular Institute, Atrium Health, Charlotte, North Carolina, USA.

Shashank S Sinha (SS)

Inova Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.

Eric I Jeng (EI)

Department of Surgery, Division of Cardiovascular Surgery, University of Florida, Gainesville, Florida, USA.

Rohan M Goswami (RM)

Division of Transplant, Research and Innovation, Mayo Clinic in Florida, Jacksonville, Florida, USA.

David F Snipelisky (DF)

Section of Heart Failure & Cardiac Transplant Medicine, Cleveland Clinic Florida, Weston, Florida, USA.

Aubrie M Carroll (AM)

Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Samer S Najjar (SS)

Medstar Heart and Vascular Institute, Baltimore, Maryland, USA.

Mark Belkin (M)

Department of Medicine, Section of Cardiology, University of Chicago, Chicago, Illinois, USA.

Jonathan Grinstein (J)

Department of Medicine, Section of Cardiology, University of Chicago, Chicago, Illinois, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH